The compounded GLP-1 market grew faster than any regulatory system could keep up with. Between 2022 and 2025, hundreds of pharmacies, telehealth platforms, and online storefronts began offering compounded semaglutide and tirzepatide at a fraction of brand-name costs. Most were legitimate. Some were not. And the consequences for patients who ended up with the wrong provider have been serious.
The FDA's enforcement data tells part of the story: over 455 adverse event reports linked to compounded semaglutide, including dosing errors, contamination, hospitalizations, and counterfeit products. More than 50 warning letters have been sent to compounders and telehealth practices since 2025.
With the regulatory landscape tightening in 2026 — the 503B exclusion proposal, shortage resolutions, and ongoing enforcement — the risk of encountering a non-compliant or unsafe provider is actually increasing, as some operators try to continue selling product outside legal boundaries.
This checklist is designed to help you verify that your compounding pharmacy meets the minimum standards for safety and legality in 2026.
The Verification Checklist
1. State Pharmacy License
Every compounding pharmacy must hold an active license from the state board of pharmacy in the state where it operates. This is the most basic requirement, and verifying it takes less than five minutes. Most state pharmacy boards have online license lookup tools. If a pharmacy cannot provide its state license number, or if that number does not verify on the state board's website, stop there.
2. 503A or 503B Registration
A legitimate compounding pharmacy operates under either Section 503A (state-licensed, patient-specific prescriptions) or Section 503B (FDA-registered outsourcing facility). 503B facilities are listed in the FDA's public database of registered outsourcing facilities. If a pharmacy claims to be a 503B facility, you can verify their registration at FDA.gov's outsourcing facility database.
3. LegitScript Certification
LegitScript is an independent verification service that certifies pharmacies for compliance with pharmacy laws, licensing requirements, and patient safety standards. While not mandatory, LegitScript certification is a strong signal that a pharmacy has submitted to independent review. You can verify certification at legitscript.com/verify.
4. Valid Prescriber-Patient Relationship
A legitimate provider will not ship you a compounded GLP-1 medication without a valid prescription from a licensed prescriber who has evaluated your medical history. If a website offers to sell you compounded semaglutide without any medical screening, questionnaire, or prescriber consultation, it is operating outside the law.
5. Clear Labeling and Dosing
Compounded medications should arrive with clear labeling that includes the active ingredient, concentration, lot number, beyond-use date, and the name and address of the compounding pharmacy. Vague or missing labeling is a serious red flag. Dosing instructions should be specific and consistent with your prescriber's orders.
6. No Claims of FDA Approval
Compounded medications are, by definition, not FDA-approved. Any pharmacy or telehealth platform that markets its compounded product as "FDA-approved" or implies equivalence to Wegovy, Ozempic, Mounjaro, or Zepbound is making a false claim. The FDA has specifically targeted this practice in its warning letters.
Warning Signs to Walk Away Immediately:
- No prescription or medical evaluation required before purchase
- Claims that compounded product is "the same as" or "identical to" Wegovy/Ozempic
- Unable to provide state pharmacy license number
- Product arrives without clear labeling, lot number, or pharmacy contact info
- Prices that seem impossibly low (under $100/month for semaglutide)
- Shipping from outside the United States
- Payment accepted only through cryptocurrency, wire transfer, or untraceable methods
- No customer service phone number or physical address
Counterfeit Product Risks
The FDA has seized counterfeit GLP-1 products from online marketplaces and flagged products that contain the wrong active ingredient, incorrect concentrations, or no active ingredient at all. Counterfeit risk is highest when purchasing from unverified online sources, social media sellers, or international suppliers.
Legitimate compounded semaglutide or tirzepatide should arrive from a domestic pharmacy with verifiable credentials, in properly labeled vials or syringes, with documentation that ties back to your prescription and your prescriber.
The Current Legal Landscape
As of May 2026, the legal status of compounded GLP-1s is in flux. Semaglutide and tirzepatide are off the FDA drug shortage list. The FDA has proposed excluding them from the 503B bulks list (comment period through June 29, 2026). While 503A patient-specific compounding remains technically legal for formulations that are not "essentially a copy" of approved products, the boundaries are actively being litigated and enforced.
Any pharmacy that represents its current compounding activities as clearly legal and settled is either misinformed or misleading you. The honest answer in 2026 is that the legal framework is in transition, and patients should understand that their compounded supply may face disruption.
How to Verify Right Now
| What to Check | Where to Check | Time |
|---|---|---|
| State pharmacy license | Your state's board of pharmacy website | 2 min |
| 503B FDA registration | FDA.gov outsourcing facility database | 2 min |
| LegitScript certification | legitscript.com/verify | 1 min |
| FDA warning letters | FDA.gov warning letters database (search pharmacy name) | 3 min |
| BBB rating and complaints | bbb.org | 2 min |
Total verification time: under 10 minutes. For a medication you are injecting into your body, this is time well spent.
Compare Verified Providers
Our provider comparison includes pharmacy verification status, LegitScript certification, and transparent pricing for every listed provider.
Compare Providers